AVALO THERAPEUTICS INC (AVTX)
Health Care · Immunology / Monoclonal Antibody Therapeutics · NASDAQ
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
What AVALO THERAPEUTICS INC does
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized anti-IL-1β monoclonal antibody currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), with topline data expected in Q2 2026. The company is preparing for pivotal Phase 3 trials and exploring additional indications for its lead asset.
Themes: autoimmune diseases, inflammatory skin diseases, IL-1β inhibition, monoclonal antibody therapeutics, clinical-stage drug development
Fundamentals
- Price$19.83 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+111.6% 2025-08-21 close $9.37 → 2026-08-21 close $19.83
- P/En/a negative earnings
- Net margin-23254.2% as of 2026-08-24
- Gross margin+242.2% as of 2026-08-24
- ROE-77.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-86.6% as of 2026-08-24
- Revenue CAGR (3y)-85.2% SEC XBRL
- Beta0.63 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AVTX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AVALO THERAPEUTICS INC looks technically
AVALO THERAPEUTICS INC (AVTX) is trading 18.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 41 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 18.3% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 18.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $18.27 | $18.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.71 | $16.71 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 17.64. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 41 trading days ago — a "golden cross", a bullish long-term signal | 41 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($17.64 to $21.02) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.27 | $24.27 |
|---|---|---|
| From the 52-week high | it is 18.3% below its 52-week high (its highest price of the past year) | -18.3% |
| Above the 52-week low | it is 135.8% above its 52-week low (its lowest price of the past year) | +135.8% |
| Below the 52-week high | it is 18.3% below its highest point of the past year | 18.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $22032.00 (set on 2019-02-27) | $22032.00 |
| Given back of the 52-week move | over the past year its closes ranged ($9.02 to $22.87), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.87 to $14.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.9% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 2.9% above a support level at $19.26 — a price it turned at three times since 2025-10-21, most recently on 2026-03-04. Since 2024-08-21 it has 16 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $3.39 (set on 2025-05-14) | $3.39 |
| Above the all-time low | it is 485.0% above its all-time low | +485.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.13 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.13 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.99 and $20.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.99 – $19.30 – $20.61 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges above its 200-day average price (18.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.71× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.2% since the prior reading | -1.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 47 sessions ago and has not traded back through the level it left behind at 13.67 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 3.6% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.0 percentage points (the stock gained 5.4% while the market gained 2.3%) | +3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.4 percentage points (the stock gained 19.5% while the market gained 3.1%) | +16.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.5 percentage points (the stock gained 39.5% while the market gained 11.1%) | +28.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 91.2 percentage points (the stock gained 111.6% while the market gained 20.5%) | +91.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.1% of the share price. | +7.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $17.46 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +13.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $19.64 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +1.0% |
Price levels it has turned at before
AVTX last closed at $19.83 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.26 | Support | 2.9% below the last close | turned there three times · 2025-10-21 to 2026-03-04 |
| $20.68 | Resistance | 4.3% above the last close | turned there twice · 2025-12-11 to 2026-07-07 |
| $17.59 | Support | 11.3% below the last close | turned there twice · 2026-07-17 to 2026-08-04 |
| $17.20 | Support | 13.3% below the last close | turned there twice · 2025-12-16 to 2026-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $17.64.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a Bollinger Band volatility squeeze · Analyst price target recently CUT · beating the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$44.15 range $30.00 – $60.00; median $42.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVTX
- Consensus EPS estimate-$0.5011 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: Phase 2 LOTUS trial topline data readout in Q2 2026 is critical; failure to meet efficacy endpoints or safety concerns could derail the program and significantly impact company valuation.","Competition from established biologics: Currently approved HS treatments (adalimumab, secukinumab, bimekizumab) already achieve HiSCR50 in approximately 50% of patients, and the company must demonstrate superior efficacy or durability to compete.","Limited cash position and high cash burn: The company has a net cash position of approximately $82 million (cash + short-term investments of $82 million) as of Q1 2026 with R&D expenses of $14 million per quarter; runway and ability to fund pivotal trials and commercial operations remain uncertain."]
What changed in the latest 10-Q
AI-assisted comparison of AVTX's 10-Q filed 2026-05-13 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added company name 'Avalo Therapeutics, Inc.' reference in newer filing's Overview section (2026-05-13)
- Added announcement of positive topline results from Phase 2 LOTUS trial on May 5, 2026, with specific efficacy data: p=0.018 (150mg), p=0.015 (300mg), p=0.004 (combined), and HiSCR75 response rates of 42.2%, 42.9%, and 42.5% respectively vs. 25.6% placebo (2026-05-13)
- Added statement that abdakibart achieved 'highest absolute improvement in HiSCR75 and HiSCR50 in clinical trials of this size or larger' (2026-05-13)
- Added mention of statistically significant benefit across key secondary endpoints including HiSCR50, change in IHS4, and change in draining tunnel count (2026-05-13)
- Added note on HiSCR75 response similarity in patients with and without prior biologic exposure (2026-05-13)
- Added announcement of May 7, 2026 follow-on offering completion with specific details: 22,899,500 shares at $17.75 per share and 1,400,000 pre-funded warrants at $17.749 per warrant, gross proceeds of approximately $431.3 million, net proceeds expected approximately $405.0 million (2026-05-13)
- Added new milestone agreement dated April 26, 2026: Milestone Buyout Option and Amendment Agreement with former AlmataBio stockholders for $2.25 million upfront to buy out $15.0 million contingent milestone payment with option to pay additional $5.125 million within 90 days (2026-05-13)
- Added specific three-month period net loss of $19.6 million and negative operating cash flows of $17.7 million for period ended March 31, 2026 (2026-05-13)
- Added cash position of $82.0 million as of March 31, 2026 (2026-05-13)
- Added statement that cash and investments are sufficient to fund operations 'into 2029' (2026-05-13)
- Updated Annual Report on Form 10-K filing date from March 20, 2025 to March 23, 2026 (2026-05-13)
- Removed:
- Removed disclosure of nine-month net loss of $64.5 million and negative operating cash flows of $37.2 million for period ended September 30, 2025 (older 2025-11-06)
- Removed cash position of $111.6 million as of September 30, 2025 (older 2025-11-06)
- Removed company name reference 'Avalo Therapeutics, Inc. (the "Company," "Avalo" or "we")' from beginning of Overview (older 2025-11-06)
- Removed statement that AVTX-009 'is in a Phase 2 clinical trial' (older 2025-11-06)
- Removed statement of focus in 2025 on 'continuing to execute operationally on the development of AVTX-009' and 'progression of the Phase 2 ("LOTUS") trial' (older 2025-11-06)
- Removed statement that topline results expected 'in mid-2026' (older 2025-11-06)
- Removed October 2025 announcement of completed enrollment in Phase 2 LOTUS trial (older 2025-11-06)
- Removed September and October 2025 announcements regarding Board of Directors appointment and leadership team expansion (older 2025-11-06)
- Removed section title 'Liquidity' heading and replaced with 'Liquidity and Capital Resources, including Capital Expenditure and Cash Requirements' (newer 2026-05-13)
- Removed statement of expectation to fund operations 'into 2028' (older 2025-11-06)
- Removed detailed discussion of future funding strategies and potential dilution risks from equity offerings (older 2025-11-06)
- Removed 'Our Strategy' section with bullet points on advancing pipeline, acquiring/in-licensing complementary compounds, and out-licensing opportunities (older 2025-11-06)
- Removed FDA approval process explanation section beginning with 'There is no guarantee that our products will obtain regulatory approval' (older 2025-11-06)
- Removed reference to year ended December 31, 2024 and replaced with December 31, 2025 (2026-05-13)
- Reworded:
- Changed product name from 'AVTX-009' to 'abdakibart (AVTX-009)' with full name introduced in Overview (2026-05-13)
- Changed description from 'is in a Phase 2 clinical trial' to completed Phase 2 trial with 'Positive topline data was recently reported' (2026-05-13)
- Changed description of lead asset from 'AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa' to 'abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody' (2026-05-13)
- Changed milestone evaluation from completion of enrollment to advancement into Phase 3 registrational program (2026-05-13)
- Changed trial description from 'approximately 250 adults' to 'enrolled 253 adults' (2026-05-13)
- Changed section title from 'Liquidity' to 'Liquidity and Capital Resources, including Capital Expenditure and Cash Requirements' (2026-05-13)
- Notes:
- Newer filing text appears truncated at end of Liquidity section, cutting off mid-sentence
- Older filing text similarly truncated in 'Our Strategy' section at end of document
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 7 sells ($2M) — 3 selling insiders
- Last 90 days0 buys · 10 sells ($2M) — 3 selling insiders
- Last 180 days0 buys · 32 sells ($7M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AVTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,658,866
- Reported value $54,626,869
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AVTX had 12,950,314 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AVTX had 24.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.38 days to cover at the same settlement.
- Reported short interest (shares) 12,950,314
- Short interest (% of shares outstanding) 24.1%
- Prior settlement (shares) 12,679,040
- Reported change 2.14%
- Days to cover (reported) 14.38
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Novartis (NVS)
- UCB (UCBJY)
- Amgen (AMGN)
- Incyte (INCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVTX vs…
AVALO THERAPEUTICS INC is found in…
AVTX ranks in…
Frequently asked questions
What does AVALO THERAPEUTICS INC (AVTX) do?
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized anti-IL-1β monoclonal antibody currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), with topline data expected in Q2 2026. The company is preparing for pivotal Phase 3 trials and exploring additional indications for its lead asset.
What sector is AVALO THERAPEUTICS INC (AVTX) in?
AVALO THERAPEUTICS INC (AVTX) is classified in the Health Care sector. Its industry is Immunology / Monoclonal Antibody Therapeutics. It trades on NASDAQ.
Who are AVALO THERAPEUTICS INC's (AVTX) competitors?
Notable peers of AVALO THERAPEUTICS INC (AVTX) include AbbVie, Novartis, UCB, Amgen and Incyte. This peer set is informational only — not financial advice.
Is AVALO THERAPEUTICS INC (AVTX) overbought or oversold right now?
AVALO THERAPEUTICS INC (AVTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.